- Home
- PRAX vs CIM Comparison
PRAX vs CIM Comparison
Compare PRAX & CIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRAX
- CIM
- Stock Information
- Founded
- PRAX 2015
- CIM 2007
- Country
- PRAX United States
- CIM United States
- Employees
- PRAX N/A
- CIM N/A
- Industry
- PRAX Biotechnology: Pharmaceutical Preparations
- CIM Real Estate Investment Trusts
- Sector
- PRAX Health Care
- CIM Real Estate
- Exchange
- PRAX Nasdaq
- CIM Nasdaq
- Market Cap
- PRAX 950.8M
- CIM 1.1B
- IPO Year
- PRAX 2020
- CIM 2007
- Fundamental
- Price
- PRAX $47.08
- CIM $13.63
- Analyst Decision
- PRAX Strong Buy
- CIM Buy
- Analyst Count
- PRAX 10
- CIM 3
- Target Price
- PRAX $102.00
- CIM $15.50
- AVG Volume (30 Days)
- PRAX 578.2K
- CIM 502.2K
- Earning Date
- PRAX 08-04-2025
- CIM 08-06-2025
- Dividend Yield
- PRAX N/A
- CIM 10.87%
- EPS Growth
- PRAX N/A
- CIM N/A
- EPS
- PRAX N/A
- CIM 1.28
- Revenue
- PRAX $7,765,000.00
- CIM $312,281,000.00
- Revenue This Year
- PRAX N/A
- CIM $18.51
- Revenue Next Year
- PRAX $3,567.38
- CIM $3.88
- P/E Ratio
- PRAX N/A
- CIM $10.60
- Revenue Growth
- PRAX 338.45
- CIM 1.91
- 52 Week Low
- PRAX $26.70
- CIM $9.85
- 52 Week High
- PRAX $91.83
- CIM $16.89
- Technical
- Relative Strength Index (RSI)
- PRAX 42.83
- CIM 48.70
- Support Level
- PRAX $44.25
- CIM $13.29
- Resistance Level
- PRAX $49.97
- CIM $13.85
- Average True Range (ATR)
- PRAX 3.36
- CIM 0.27
- MACD
- PRAX -0.89
- CIM 0.01
- Stochastic Oscillator
- PRAX 18.84
- CIM 68.70
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.
About CIM Chimera Investment Corporation
Chimera Investment Corporation is a real estate investment trust engaged in investing in a portfolio of mortgage assets on a leveraged basis. These investments include a variety of government-sponsored agency residential mortgage-backed securities, or RMBS, non-agency RMBS, agency commercial mortgage-backed securities, residential mortgage loans, and other real estate-related securities. Agency mortgage-backed securities represent the share of this portfolio, while subprime residential mortgage loans and non-agency RMBS also make up substantial shares.